• Prescribing Information
  • Medical Information
  • Welcome to TruSupport

    Pfizer TruSupport​​​​​​​​​​​​​​​​​​​​

    • Ordering options
    • Patient coverage confirmation
    • Essential tools
    • Resources for your practice
    Card CTA

    Ordering & Inventory with TruSupport

    Provides multiple convenient options for ordering TRUMENBA​​​​​​

    View the options

    Coverage & Reimbursement with TruSupport

    Streamlines the processes of confirming your patient's coverage for TRUMENBA

    Learn how Pfizer streamlines

    Patient Adherence

    Tools to help your patients start and stay on track with the TRUMENBA series

    Learn about these tools

    Click here to access TRUMENBA resources for download to share with your office staff and patients

    The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

    TRUMENBA resources

    ** This is an optional area where footnotes can live.

    Contact your Pfizer Sales Representative to learn more about these services.


    Reference:
    1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.

    Support & Order

    • Welcome to TruSupport
    • Ordering & Inventory
    • Coverage & Reimbursement
    • Patient Adherence

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​